. 2009 Jul 8;4(7):e6184. doi: 10.1371/journal.pone.0006184

Table 4. B cells (CD19⁺) in the CSF of HAT patients and controls.

	Control group n = 4	S-1 patients n = 8	S-int patients n = 8	S-2 patients n = 13
Total CSF cell count *(cells/µl)*	1.7±1.3	2.4±0.9	8.3±1.7	477.7±426.6
CD19⁺ B-cell count *(cells/µl)*	0.01±0.01^*	0.11±0.10^¤	0.5±0.36^•	243.70±254.26^* ^¤ ^•
CD19⁺ B-cell %	0.7±0.5^*	4±5^¤	5.9±5.8^•	51.1±23.3^* ^¤ ^•

HAT Patients were at stage 1 (S-1), intermediate stage (S-int) or stage 2 (S-2). B cells (CD 19⁺) are expressed as means±standard deviation of absolute values and as a percentage of total CSF cell count. Note: P<0.05 for statistical differences.

S-2 patients vs control.

^¤

S-1 vs S-2 patients.

^•

S-int vs S-2 patients.

Table 4. B cells (CD19+) in the CSF of HAT patients and controls.

Table 4. B cells (CD19⁺) in the CSF of HAT patients and controls.